Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Jacksonville, Florida 32207


Purpose:

The purpose of this study is to see if Arimidex, an aromatase inhibitor, can delay epiphyseal fusion and increase predicted adult height in boys who are growth hormone deficient, in puberty, and who are taking growth hormone. This is a double blind, placebo controlled 3 year trial.


Criteria:

Inclusion Criteria: - Growth hormone deficient by formal testing with two provocative agents. - Treated with growth hormone for a minimum of 6 months prior to study entry. - Growth hormone doses must be maintained at 0.2-0.4mg/kg/wk while in protocol. - Stable organic pathology - Presence of puberty [genital Tanner Stage > II (>4cc testicular volume)] - Bone age (BA) > or = 11.5 years and < 15 years Exclusion Criteria: - Participation in any other trial involving hormone therapy for at least 6 months prior. - Chronic illnesses requiring long term medication that impair growth. (Stable patients with occasional asthma, patients on Ritalin or Adderall or patients on topical acne medication may be included). - Hereditary disease diagnosed clinically. - Moderate to severe scoliosis.


NCT ID:

NCT00133354


Primary Contact:

Principal Investigator
Nelly Mauras, MD
Nemours Children's Clinic


Backup Contact:

N/A


Location Contact:

Jacksonville, Florida 32207
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 14, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.